| Dr Amnon Schlegel, MD, PHD | |
|
7410 S Creek Rd Ste 100, Sandy, UT 84093-6151 | |
| (801) 816-1010 | |
| (801) 515-0045 |
| Full Name | Dr Amnon Schlegel |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Endocrinology, Diabetes & Metabolism |
| Location | 7410 S Creek Rd Ste 100, Sandy, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093910796 | NPI | - | NPPES |
| Entity Name | University Of Utah Adult Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114321981 PECOS PAC ID: 0941525273 Enrollment ID: O20150209001683 |
News Archive
Ninety percent of cancer deaths resulted from metastasis, the spread of cancer to different areas in the body, yet scientific exploration of the possible mechanical factors that promote metastasis has been limited.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.
On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) today signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate in target-based screening for the discovery of new tuberculosis (TB) drugs.
› Verified 4 days ago
| Entity Name | Healthy Mindset Intl Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1295351278 PECOS PAC ID: 4284046335 Enrollment ID: O20201214001429 |
News Archive
Ninety percent of cancer deaths resulted from metastasis, the spread of cancer to different areas in the body, yet scientific exploration of the possible mechanical factors that promote metastasis has been limited.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.
On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) today signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate in target-based screening for the discovery of new tuberculosis (TB) drugs.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amnon Schlegel, MD, PHD 7410 S Creek Rd Ste 100, Sandy, UT 84093-6151 Ph: (801) 816-1010 | Dr Amnon Schlegel, MD, PHD 7410 S Creek Rd Ste 100, Sandy, UT 84093-6151 Ph: (801) 816-1010 |
News Archive
Ninety percent of cancer deaths resulted from metastasis, the spread of cancer to different areas in the body, yet scientific exploration of the possible mechanical factors that promote metastasis has been limited.
Researchers in the U.S. say that obese men have lower levels of a protein used to screen for prostate cancer risk, and doctors should take weight into account when determining a man's risk.
Merck, known as MSD outside the United States and Canada, today provided an update on the clinical program for preladenant, Merck's investigational adenosine A2A receptor antagonist for the treatment of Parkinson's disease.
On behalf of The Lilly TB Drug Discovery Initiative, the Infectious Disease Research Institute (IDRI) today signed a Memorandum of Understanding (MOU) with Academia Sinica, a research institution based in Taiwan, to collaborate in target-based screening for the discovery of new tuberculosis (TB) drugs.
› Verified 4 days ago
Dr. Robert Kyle Barnett, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 1393 E Sego Lily Dr, Sandy, UT 84092 Phone: 801-619-9000 Fax: 801-619-9001 | |
Dr. Timothy E Graham, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 7410 S Creek Rd Ste 100, Sandy, UT 84093 Phone: 801-816-1010 Fax: 801-515-0045 | |
Dr. Keith L Ritchie, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 1508 River Oaks Dr, Sandy, UT 84093 Phone: 801-943-7834 Fax: 801-944-3038 | |
Dr. Richard B Gremillion, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 11333 S 1000 E, Ste 100, Sandy, UT 84094 Phone: 801-571-4100 Fax: 801-571-4125 | |
Thomas M Dietz, MD Endocrinology, Diabetes & Metabolism Medicare: Not Enrolled in Medicare Practice Location: 9844 S 1300 E, #200, Sandy, UT 84094 Phone: 801-572-1472 | |
Tanya K Powel, MD Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 9350 S 150 E Ste 150, Sandy, UT 84070 Phone: 180-190-3566 Fax: 180-198-4828 |